Health AI Central
Share:
Peer-Reviewed Publication
Diabetes Technol Ther2026;28(5):483-489.May 1, 2026Journal Article

Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System.

Carol J Levy1, Daniel Carlow2, Dan Swift2, Rana Rittgers-Simonds2, Noelle N Gronroos3, Valery Walker3, Erin K Buysman3, Gregory Forlenza4
1Division of Endocrinology, Diabetes, and Metabolism, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.
2Insulet Corporation, Acton, Massachusetts, USA.
3Optum, Eden Prairie, Minnesota, USA.
4Department of Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
PubMed DOI

Abstract

INTRODUCTION: The Omnipod® 5 Automated Insulin Delivery (AID) System is the first wearable, on-body, tubeless AID system in the United States. Clinical trials have demonstrated hemoglobin A1C (HbA1c) improvements with Omnipod 5 use. The aim of the study was to evaluate HbA1c changes after initiating Omnipod 5 in a real-world setting. METHODS: This retrospective study utilized commercial and Medic…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.